Cutaneous Adverse Events Associated with BRAF and MEK Inhibitors: a Systematic Review and Meta-analysis

Overview

Journal Front Pharmacol

Date 2025 Jan 8

PMID 39776585

Authors

Junhui Qian

Jinlong Wan

Qin Yao

Yin Chen

Tao Ling

Yuejuan Zhang

Zhihua Tang

Affiliations

Soon will be listed here.

Abstract

Aim: Cutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor treatment with CAEs in patients with melanoma compared with BRAF inhibitor alone.

Method: PubMed, Cochrane, Embase and Web of Science were systematically searched for BRAF and MEK inhibitors from database inception through 10 May 2024. Randomized clinical trials reporting on CAEs in patients with melanoma being treated with BRAF and MEK inhibitors compared with patients with melanoma being treated with BRAF inhibitor monotherapy were selected. Pooled Risk ratios (RRs) and 95% CIs were determined using random-effects analyses. The selected end points were alopecia, cutaneous squamous-cell carcinoma, hyperkeratosis, keratoacanthoma, palmoplantar erythrodysaesthesia syndrome, palmoplantar keratoderma, rash, photosensitivity reaction, and skin papilloma. All-grade and high-grade (≥3) CAEs were recorded.

Results: Comparing with BRAF and MEK inhibitors, treatment with BRAF inhibitors alone was associated with an increased risk of rash (RR, 0.73; 95% CI, 0.54-0.99; = 0.039; I = 88%), alopecia (RR, 0.28; 95% CI, 0.20-0.41; P < 0.001; I = 76%), hyperkeratosis (RR, 0.30; 95% CI, 0.22-0.41; P < 0.001; I = 56%), palmoplantar erythrodysaesthesia syndrome (RR, 0.21; 95% CI, 0.10-0.47; P < 0.001; I = 81%), palmoplantar keratoderma (RR, 0.39; 95% CI, 0.26-0.57; P < 0.001; I = 29%), Skin papilloma (RR, 0.25; 95% CI, 0.12-0.52; P < 0.001; I = 77%), cutaneous squamous-cell carcinoma (RR, 0.21; 95% CI, 0.11-0.42; P < 0.001; I = 50%), and keratoacanthoma (RR, 0.22; 95% CI, 0.12-0.40; P < 0.001; I = 0%).

Conclusion: Therapy with BRAF and MEK inhibitors was associated with a lower risk of CAEs, especially rash, alopecia, hyperkeratosis, palmoplantar erythrodysaesthesia syndrome, palmoplantar keratoderma, skin papilloma, cutaneous squamous-cell carcinoma, and keratoacanthoma, compared with BRAF inhibitor alone. The risks of photosensitivity reaction was similar between the assessed groups. The findings may help to balance between beneficial melanoma treatment and cutaneous morbidity and mortality.

References

Dummer R, Rinderknecht J, Goldinger S . Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012; 366(5):480-1. DOI: 10.1056/NEJMc1113752. View

Anforth R, Tembe V, Blumetti T, Fernandez-Penas P . Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 2012; 25(5):569-72. DOI: 10.1111/j.1755-148X.2012.01031.x. View

Zhao F, Zhu J, Yu R, Shao T, Chen S, Zhang G . Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. Sci Rep. 2022; 12(1):20038. PMC: 9681870. DOI: 10.1038/s41598-022-24286-3. View

Califano I, Smulever A, Jerkovich F, Pitoia F . Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. Rev Endocr Metab Disord. 2023; 25(1):123-147. DOI: 10.1007/s11154-023-09833-1. View

Mattei P, Alora-Palli M, Kraft S, Lawrence D, Flaherty K, Kimball A . Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2012; 24(2):530-537. DOI: 10.1093/annonc/mds292. View

Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski T, Daud A . Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014; 15(9):954-65. DOI: 10.1016/S1470-2045(14)70301-8. View

Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A . Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2013; 55(4):250-4. DOI: 10.1111/ajd.12124. View

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O . RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3):207-15. PMC: 3724537. DOI: 10.1056/NEJMoa1105358. View

Flaherty K, Infante J, Daud A, Gonzalez R, Kefford R, Sosman J . Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18):1694-703. PMC: 3549295. DOI: 10.1056/NEJMoa1210093. View

10.

Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K . Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014; 71(6):1102-1109.e1. PMC: 4254519. DOI: 10.1016/j.jaad.2014.09.002. View

11.

Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E . Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. Am J Clin Dermatol. 2021; 23(2):247-255. DOI: 10.1007/s40257-021-00645-0. View

12.

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

13.

Viera A . Odds ratios and risk ratios: what's the difference and why does it matter?. South Med J. 2008; 101(7):730-4. DOI: 10.1097/SMJ.0b013e31817a7ee4. View

14.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

15.

Flaherty K, Robert C, Hersey P, Nathan P, Garbe C, Milhem M . Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2):107-14. DOI: 10.1056/NEJMoa1203421. View

16.

Long G, Flaherty K, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F . Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017; 28(7):1631-1639. PMC: 5834102. DOI: 10.1093/annonc/mdx176. View

17.

Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G . Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19(10):1315-1327. DOI: 10.1016/S1470-2045(18)30497-2. View

18.

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

19.

Dzwierzynski W . Melanoma Risk Factors and Prevention. Clin Plast Surg. 2021; 48(4):543-550. DOI: 10.1016/j.cps.2021.05.001. View

20.

Yelamos O, Merkel E, Sholl L, Zhang B, Amin S, Lee C . Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi. J Invest Dermatol. 2016; 136(9):1858-1865. PMC: 5031419. DOI: 10.1016/j.jid.2016.05.094. View